Evelo Biosciences, Inc. (EVLO)

Evelo Biosciences, Inc. (NASDAQ: EVLO - Get Free Report) was the target of unusually large options trading on Wednesday. Stock investors acquired 1,885 put options on the company. This represents an increase of approximately 1,101% compared to the typical daily volume of 157 put options. Evelo Biosciences Stock Down 50.0% Evelo Biosciences stock opened at $0.00

Evelo Biosciences, Inc. (NASDAQ: EVLO - Get Free Report) was the target of some unusual options trading on Wednesday. Traders acquired 1,885 put options on the stock. This is an increase of 1,101% compared to the average daily volume of 157 put options. Evelo Biosciences Trading Down 80.0% NASDAQ: EVLO opened at $0.00 on Thursday. The company

Insider and Institutional Ownership 44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and

Evelo Biosciences, Inc. (NASDAQ: EVLO - Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors acquired 1,885 put options on the company. This is an increase of approximately 1,101% compared to the typical volume of 157 put options. Evelo Biosciences Stock Performance NASDAQ: EVLO opened at $0.00 on Thursday. The

Valuation and Earnings This table compares Antibe Therapeutics and Evelo Biosciences"s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Antibe Therapeutics $7.51 million 0.00 -$14.54 million ($0.60) N/A Evelo Biosciences N/A N/A -$114.53 million ($13.01) 0.00 Antibe Therapeutics has higher revenue and earnings than

MONTRÉAL--(BUSINESS WIRE)--EVLO Energy Storage Inc. (EVLO), a fully integrated battery energy storage systems (BESS) provider and wholly owned subsidiary of Hydro-Québec, announces a major achievement in its relationship with investor-owned utility Dominion Energy (Dominion) to develop a battery energy storage system (BESS) with enhanced fire and safety features that meet and exceed Dominion's unique safety specifications. The augmented version of EVLOFLEX now has achieved UL 9540 certification.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate.

Evelo Biosciences' shares have tumbled 46% in premarket trading after the biotech firm revealed disappointing results in a phase II psoriasis trial for its next-generation drug, EDP2939. A resounding miss, the treatment failed to outperform the placebo, which has no therapeutic effect.

Evelo Biosciences Inc. EVLO, -6.73% said Tuesday it's reviewing its strategic options and exploring partnerships after a Phase 2 study of a treatment for psoriasis failed to meet its main goal. “The study's primary endpoint, the difference in the proportion of patients who achieved an outcome of a 50% improvement from baseline in Psoriasis Area and Severity Index (PASI) score (a PASI-50 response) between EDP2939 and placebo after 16 weeks of daily treatment, was not achieved,” the company said in a statement.

- Primary endpoint was not achieved – - Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform - CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo” or the “Company”), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced top-line results from its Phase 2 clinical study with EDP2939 in moderate psoriasis.

Following recent cash raise, EVLO has enough (barely) cash to the next catalyst, phase 2 readout in psoriasis. The event is binary and can make or break the company. Prior failure of EVLO's platform in atopic dermatitis is concerning. However, psoriasis is a different indication (different pathophysiology) and de-risked by positive results in a prior phase 2 study. Ongoing phase 2 trial in psoriasis is being conducted with a second generation candidate, EDP2939, which is expected to have better efficacy and now represents EVLO's sole clinical-stage candidate.

– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023 – Completed $25.5 Million Private Placement – Restructured and reduced secured debt with Horizon Technology Finance Corporation

Restructures and reduce s secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced that it has entered into a securities purchase agreement with investors in a private placement to sell 11,025,334 shares of its common stock (the “Shares”) at a purchase price of $2.31 per share, which would result in gross proceeds of approximately $25.5 million. The offering is being led by Evelo's founder, Flagship Pioneering, with participation from other new and existing investors. Evelo intends to use the net proceeds from the private placement to fund the readout of its Phase 2a trial of EDP2939 in moderate psoriasis, to pay down approximately $5.0 million of its existing debt and for general corporate purposes.